Αρχική World News FDA Approves Cemiplimab-rwlc for Locally Advanced and Metastatic Basal Cell Carcinoma

FDA Approves Cemiplimab-rwlc for Locally Advanced and Metastatic Basal Cell Carcinoma

On 9 February 2021, the US Food and Drug Administration (FDA) granted regular approval to cemiplimab-rwlc (Libtayo, Regeneron Pharmaceuticals, Inc.) for patients with locally advanced basal cell carcinoma (laBCC) previously treated with a hedgehog pathway inhibitor (HHI) or for whom a HHI is not appropriate and granted accelerated approval to cemiplimab-rwlc for patients with metastatic BCC (mBCC) previously treated with a HHI or for whom a HHI is not appropriate.

Efficacy was evaluated in Study 1620 (NCT03132636), an ongoing open-label, multi-centre, non-randomised study in patients with advanced BCC (laBCC or mBCC) who had progressed on HHI therapy, had not had an objective response after 9 months on HHI therapy, or were intolerant of prior HHI therapy. Eligibility required that laBCC patients were not candidates for curative surgery or curative radiotherapy, per multidisciplinary assessment.  All patients received cemiplimab-rwlc 350 mg every 3 weeks for up to 93 weeks until disease progression, unacceptable toxicity, or completion of planned treatment.

The main efficacy outcome measures were confirmed objective response rate (ORR) and duration of response (DoR) as assessed by independent central review. For patients without externally visible target lesions (mBCC), confirmed ORR was assessed according to RECIST v1.1. A composite response assessment incorporating clinical response criteria using digital medical photography together with RECIST v1.1, was used for those with externally visible target lesions (laBCC and mBCC).

Among 84 patients with laBCC, the confirmed ORR was 29% (95% confidence interval [CI] 19, 40) with a median DoR not reached (range: 2.1 to 21.4+ months) and 79% of responders maintaining their response for at least 6 months.  Among 28 patients with mBCC, the confirmed ORR was 21% (95% CI 8, 41) with a median DoR not reached (range: 9 to 23.0+ months), and all responders maintaining their responses for at least 6 months.

Severe adverse reactions are immune-mediated adverse reactions (e.g. pneumonitis, hepatitis, colitis, adrenal insufficiency, hypo- and hyperthyroidism, diabetes mellitus and nephritis) and infusion reactions. The most common adverse reactions (incidence ≥ 20%) were fatigue, musculoskeletal pain, diarrhoea, rash, and pruritis.  

The recommended dosage of cemiplimab-rwlc is 350 mg as an intravenous infusion over 30 minutes every 3 weeks until disease progression or unacceptable toxicity.

Full prescribing information for Libtavo is available here.

This review used the Assessment Aid, a voluntary submission from the applicant to facilitate the FDA’s assessment.

This application was granted priority review.

Healthcare professionals should report all serious adverse events suspected to be associated with the use of any medicine and device to FDA’s MedWatch Reporting System.

For assistance with single-patient INDs for investigational oncology products, healthcare professionals may contact FDA’s Oncology Center of Excellence Project Facilitate.

Source

NEWSLETTER

Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like
57ΑκόλουθοιΑκολουθήστε

Διαβαστε Επίσης

Καρκίνος και Κορωνοϊός (COVID-19) ΜΕΡΟΣ Α

Εάν είστε καρκινοπαθής, το ανοσοποιητικό σας σύστημα μπορεί να μην είναι τόσο ισχυρό όσο κανονικά, έτσι μπορεί να ανησυχείτε για τους κινδύνους που σχετίζονται...

ΠΑΓΚΟΣΜΙΑ ΗΜΕΡΑ ΚΑΡΚΙΝΟΥ

Η Παγκόσμια Ημέρα Κατά του Καρκίνου καθιερώθηκε με πρωτοβουλία της Διεθνούς Ένωσης κατά του Καρκίνου (UICC), που εκπροσωπεί 800 οργανώσεις σε 155 χώρες του...

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ)

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...
- Advertisment -

Ροή Ειδήσεων

FDA Approves Pembrolizumab Combination for the First-Line Treatment of Cervical Cancer

On 13 October 2021, the US Food and Drug Administration (FDA) approved pembrolizumab (Keytruda, Merck) in combination with chemotherapy, with or without bevacizumab, for...

From Scan to Scan: The Challenges of Living with Metastatic Cancer

October 15, 2021, by NCI Staff Bethany Ross has been living with metastatic neuroendocrine cancer since she was diagnosed in 2018. Credit: Used with permission from...

The award-winning researcher behind next generation sequencing

Next generation sequencing (NGS) has given the genomic research community ultra-high throughput, scalability, and speed that could only be dreamed of 20 years ago....

Many Breast Cancer Patients Use Cannabis to Manage Symptoms But Don’t Tell Their Doctors

Cancer and cancer treatment come with many side effects, including nausea, vomiting, and pain. In addition to the physical toll, the impacts to a...

Medicare Open Enrollment Starts Tomorrow!

Medicare open enrollment is upon us for 2022. If you are a Medicare recipient, this is the time of year when you can make...

Cancer in My Community: Providing Supportive Care in Serbia

Cancer in My Community is a Cancer.Net Blog series that shows the global impact of cancer and how people work to care for those with...